Clopidogrel resistance is common (32%) among Jordanian cardiovascular patients and is significantly associated with female gender, calcium channel blocker use, low HDL, and the CYP2C19*2 polymorphism.
Answers are grounded in this paper and cite their sources.
Clopidogrel resistance factors should not yet guide therapy; leaves open whether CYP2C19 testing improves outcomes in prospective studies.
BACKGROUND AND OBJECTIVE: Clopidogrel is a potent antiplatelet drug that reduces the risk of vascular events in patients with cardiovascular disease. However, several studies have shown that about a quarter of patients showed low or no response to clopidogrel therapy. In this study, factors that contribute to clopidogrel resistance were investigated in 270 cardiovascular disease patients from Jordan. PATIENTS AND METHODS: Clopidogrel resistance was determined through platelet aggregation analysis using the Multiplate analyzer®. Genetic factors (CYP2C19*2 and PON1 Q192R) were examined using polymerase chain reaction-restriction fragment length polymorphism analysis. RESULTS: The incidence of clopidogrel resistance among Jordanians is about 32%. Significant association between clopidogrel resistance and female gender, concomitant use of calcium channel blockers, and low HDL was found (p < 0.05). In addition, presence of CYP2C19*2 allele is strongly related to clopidogrel resistance (p < 0.001). However, lack of contribution to clipidogrel resistance was found for PON1 Q192R polymorphism, age, diabetes, hypertension, smoking and aspirin use (p > 0.05). CONCLUSION: Several factors might contribute to clopidogrel resistance including gender, concomitant use of calcium channel blockers, HDL and CYP2C19*2 polymorphism.
No takes yet. Share an insight, caveat, or question.
Al‐Azzam et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: